Clinical Trials

ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo

ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).

Lilly’s mirikizumab superior to Cosentyx in phase 3 study for patients with moderate to severe plaque psoriasis

Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study.

Sinopharm begins phase 3 trial of Covid-19 inactivated vaccine candidate

Chinese vaccine manufacturer Sinopharm CNBG has started a phase 3 trial of its Covid-19 inactivated vaccine candidate in the UAE.

Celltrion begins Covid-19 human clinical trial with antiviral antibody treatment

Celltrion Group has commenced phase 1 human clinical study to assess the potential of its antiviral antibody treatment for patients with Covid-19.

Brilinta significantly reduced rate of composite of stroke and death in THALES trial

Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 [95% CI 0.71, 0.96], p=0.02), compared to aspirin alone in patients who had an acute ischemic stroke or transient ischemic attack (TIA).

BioAegis Therapeutics receives approval to proceed with phase 2 trial of its gelsolin Covid-19 treatment

BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in hospitalized patients with severe COVID-19 pneumonia.

Medicago starts phase I clinical trials with Covid-19 vaccine candidate

Biopharmaceutical firm Medicago has commenced the phase I clinical trials with its plant-derived Covid-19 vaccine candidate.

Rocket Pharmaceuticals treats first patient in phase 1 trial of RP-L301 for PKD

Rocket Pharmaceuticals said that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Pyruvate Kinase Deficiency (PKD), a rare monogenic red blood cell disorder.

Glenmark commences 1000 patients post marketing surveillance study with Covid-19 who are administered FabiFlu

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.